Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1989 1
2009 1
2015 2
2016 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS 3rd, Hilliard L, Bemrich-Stolz CJ, Howard TH, Johnston JM. Griessenauer CJ, et al. J Neurosurg Pediatr. 2015 Jul;16(1):64-73. doi: 10.3171/2014.12.PEDS14522. Epub 2015 Apr 3. J Neurosurg Pediatr. 2015. PMID: 25837886
OBJECT Pediatric patients with sickle cell disease (SCD) and moyamoya syndrome (MMS) are at significant risk for cerebrovascular accidents despite chronic transfusion therapy. ...METHODS The authors retrospectively reviewed the cases of all pediatric patients …
OBJECT Pediatric patients with sickle cell disease (SCD) and moyamoya syndrome (MMS) are at significant risk for cerebrovascul …
Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population.
Capalbo A, Fabiani M, Caroselli S, Poli M, Girardi L, Patassini C, Favero F, Cimadomo D, Vaiarelli A, Simon C, Rienzi LF, Ubaldi FM. Capalbo A, et al. Hum Reprod. 2021 Jun 18;36(7):2050-2061. doi: 10.1093/humrep/deab087. Hum Reprod. 2021. PMID: 34021342
Of the identified ARCs, 5 (0.7%) were at risk for cystic fibrosis, 5 (0.7%) for fragile X syndrome, 4 (0.5%) for spinal muscular atrophy, 4 (0.5%) for Beta-Thalassemia/Sickle Cell Anemia, 1 (0.1%) for Smith-Lemli-Opitz Syndrome and 1 (0.1%) for Duchenn …
Of the identified ARCs, 5 (0.7%) were at risk for cystic fibrosis, 5 (0.7%) for fragile X syndrome, 4 (0.5%) for spinal muscular atrophy, 4 …
Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
Kunz JB, Awad S, Happich M, Muckenthaler L, Lindner M, Gramer G, Okun JG, Hoffmann GF, Bruckner T, Muckenthaler MU, Kulozik AE. Kunz JB, et al. Ann Hematol. 2016 Feb;95(3):397-402. doi: 10.1007/s00277-015-2573-y. Epub 2015 Dec 12. Ann Hematol. 2016. PMID: 26658910
Children with sickle cell disease (SCD) benefit from newborn screening, because life-threatening complications can be prevented by pre-symptomatic diagnosis. ...We identified 83 carriers of the sickle cell trait, three compound heterozygous SCD patient …
Children with sickle cell disease (SCD) benefit from newborn screening, because life-threatening complications can be prevente …
Sickle cell crisis treated by exchange transfusion. Treatment of two patients with heterozygous sickle cell syndrome.
Green M, Hall RJ, Huntsman RG, Lawson A, Pearson TC, Wheeler PC. Green M, et al. JAMA. 1975 Mar 3;231(9):948-50. JAMA. 1975. PMID: 1173102
The one patient, with sickle cell beta thalassemia, achieved a 90% exchange, calculated on the sickle cell hemoglobin present before and after transfusion. The other patient, with sickle cell hemoglobin Hb A, S, and (Hb) C d …
The one patient, with sickle cell beta thalassemia, achieved a 90% exchange, calculated on the sickle …
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Imran F, Phatak P. Imran F, et al. Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):297-304. doi: 10.1586/erp.09.26. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19670988
Deferasirox is a once-daily, orally administered, tridentate iron chelator that is indicated in the treatment of iron overload resulting from regular packed red blood cell transfusions in patients with transfusion-dependent anemias, such as beta-thalassemia, …
Deferasirox is a once-daily, orally administered, tridentate iron chelator that is indicated in the treatment of iron overload resulting fro …